Aptevo Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia

 

• Aptevo Therapeutics Inc APVO 3.09% has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).
• The study met its primary endpoint of identification of an active dose level for advanced studies.
• The Company plans to submit the data for publication later this year.
• Of seven evaluable relapsed AML patients treated in Cohort 6, four showed stabilization of their leukemias.
• Of those four patients with disease stabilization, three patients lived over 246 days, over 261 days, and over 281 days, respectively, and one progressed after a month.
• Two relapsed AML patients, who experienced stabilization of their leukemia, achieved partial remission and subsequently a complete remission.
• No partial or complete remissions have been observed at APVO436 dose levels either lower or higher than the Cohort 6 dose level.
• APVO436 was generally well tolerated and demonstrated a favorable side effect profile, including the absence of severe or prolonged neutropenia, an often serious condition associated with CD123-targeting therapies.

https://www.benzinga.com/general/biotech/21/05/21297990/aptevo-stock-gains-on-encouraging-single-agent-activity-for-apvo436-in-leukemia-patients